Top

Published in:

Open Access 01-06-2021 | Stroke | Review

SARS-CoV-2 Infection: Symptoms of the Nervous System and Implications for Therapy in Neurological Disorders

Author: Jacek Losy

Published in: Neurology and Therapy | Issue 1/2021

Abstract

In this paper, the neurological aspects of COVID-19 are presented, which may be of significance for physicians. Knowledge about the neurological symptoms of COVID-19 infection should help physicians in diagnoses and in taking appropriate precautions, as some manifestations can appear before typical pulmonary symptoms. Various mechanisms of SARS-CoV-2 neuroinvasion are discussed and symptoms are described, which can be subdivided into manifestations of the central nervous system (CNS) (headache, dizziness, stroke, impaired consciousness, encephalitis, meningitis, seizures) and peripheral nervous system (PNS) (characteristic hyposmia and hypogeusia, Guillain Barré syndrome, myalgia). Additionally, the implications of COVID-19 infection for treatment of patients with common neurological diseases and their management is presented. It can be concluded that neurological symptoms are part of a clinical spectrum of COVID-19 infection, involving the CNS and PNS. COVID-19 may influence decisions regarding the treatment of neurological disorders, especially those with an immune background.

Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382:727–33.CrossRefPubMedPubMedCentral

Mingxuan X, Qiong C. Insight into 2019 novel coronavirus-an updated interim review and lessons from SARS-Cov and MERS-Cov. Int J Infect Dis. 2020;94:119–24.CrossRef

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID 19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.CrossRefPubMedPubMedCentral

Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020. https://doi.org/10.1016/j.inf.2020.03.0.CrossRefPubMedPubMedCentral

Zhou P, Yang XL, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.CrossRefPubMedPubMedCentral

Patel AB, Vermas A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence? JAMA. 2020;323:1769–70.CrossRefPubMed

Chen R, Wang K, Yu J, Zhong C, Wen C, Xu Z. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. BioRxiv. 2020. https://doi.org/10.1101/2020.04.07.030650.CrossRefPubMedPubMedCentral

Zubair AS, Mc Alpine LS, Gardin T, Farhadian S, Kuruvlla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of Coronavirus Disease 2019. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.2065.CrossRefPubMedPubMedCentral

Tu H, Tu S, Gao S, Shao A, Sheng J. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. J Infect. 2020. https://doi.org/10.1016//j.inf.2020.04.011.CrossRefPubMedPubMedCentral

10.

Vandenbark A, Meza-Romero R, Offner H. Surviving the storm. Dealing with COVID-19. Cell Immunol. 2020. https://doi.org/10.1016/j.cellimm.2020.104153.CrossRefPubMedPubMedCentral

11.

Mao L, Wang M, Hu Y, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.1127.CrossRefPubMedPubMedCentral

12.

Helms J, Kremer S, Merdji H, et al. Neurologic features ion severe SARS-CoV-2 infection. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2008597.CrossRefPubMedPubMedCentral

13.

Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study retrospective study. BMJ. 2020. https://doi.org/10.1136/bmj.m1091.CrossRefPubMedPubMedCentral

14.

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.CrossRefPubMedPubMedCentral

15.

Frontera JA, Sabadia S, La Ichan R, et al. A prospective study of neurological disorders in hospitalized COVID-19 patients in New York city. Neurology. 2020. https://doi.org/10.12112/WNL.0000000000010979.CrossRefPubMedPubMedCentral

16.

Lahiri D, Ardila A. COVID-19 pandemic: a neurological perspective. Cureus. 2020. https://doi.org/10.7759/cureus.7889.CrossRefPubMedPubMedCentral

17.

Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associate with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55–8.CrossRefPubMedPubMedCentral

18.

Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. Brain Behav Immun. 2020. https://doi.org/10.1016/j.bbi.2020.04.024.CrossRefPubMedPubMedCentral

19.

Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic encephalopathy: CT and MRI features. Radiology. 2020. https://doi.org/10.1148/radiol.2020201187.CrossRefPubMed

20.

Li Y, Wang M, Zhou Y et al. Cerebrovascular disease following COVID-19: a single center, retrospective observational study SVN. 2020.

21.

Klok FA, Kruip MJ, van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.CrossRefPubMedPubMedCentral

22.

Yaghi S, Ishida K, Torres J, et al. Stroke in a New York healthcare system. Stroke. 2020. https://doi.org/10.1161/STROKEAHA.1200.CrossRefPubMedPubMedCentral

23.

Oxley T, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of COVID-19 in young. N Engl J Med. 2020. https://doi.org/10.1056/NEJM:c2009787.CrossRefPubMedPubMedCentral

24.

Malentacchi M, Gned D, Angelino V, et al. Concomitant brain arterial and venous thrombosis in a COVID-19 patient. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14380.CrossRefPubMedPubMedCentral

25.

Yan CH, Faraji F, Prajapati DP, Boone CE, DeCoonde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020. https://doi.org/10.1002/air.22579.CrossRefPubMedPubMedCentral

26.

Lechien JR, Chiesa-Estomba CM, De Siati DR. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020. https://doi.org/10.1007/s00405-020-05965-1.CrossRefPubMedPubMedCentral

27.

Spinato G, Fabbris C, Polesel J, et al. Alterations in smell and taste in mildly symptomaqtic outpatients with SARS-CoV-2 infection. JAMA. 2020;323:2089–90.CrossRefPubMedPubMedCentral

28.

Chiu A, Fischbein N, Wintermatk M, et al. COVID-19-induced anosmia associated with olfactory bulb atrophy. Neuroradiology. 2020. https://doi.org/10.1007/s00234-020-02554-1.CrossRefPubMedPubMedCentral

29.

Parauda SC, Gao V, Gewirtz AN, et al. Posterior reversible encephalopathy syndrome in patients with COVID-19. J Neurol Sci. 2020. https://doi.org/10.1016/j.jns.2020.117019.CrossRefPubMedPubMedCentral

30.

Liansó L, Urra X. Posterior reversible encephalopathy syndrome in COVID-19 disease: a case report. SN Compr Clin Med. 2020. https://doi.org/10.1007/s42399-020-00470-2.CrossRef

31.

Anand P, Vincent Lau KH, Chung DY, et al. Posterior reversible encephalopathy syndrome in patients with coronavirus disease 2019: two cases and a review of the literature. J Stroke Cerebrovasc Dis. 2019;2020:1.

32.

Zhao K, Huang J, Dai D, Feng Y, Liu L, Nie S. Acute myelitis after SARS-CoV-2 infection: a case report. 2020. https://www.medrxv.org/content/10.1101/2020.0316.20035105v2

33.

Sedaghat Z, Karimi N. Guillain Barré syndrome associated with COVID-19 infection: a case report. J Clin Neurosci. 2020;76:223–35.CrossRef

34.

Toscano G, Palmerini F, Ravavaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2009191.CrossRefPubMedPubMedCentral

35.

Virani A, Rabold E, Hanson T, et al. Guillain-Barré Syndrome associated with SARS-CoV-2 infection. ID Cases. 2020. https://doi.org/10.1016/j.idcr.2020e00771.CrossRefPubMedPubMedCentral

36.

Gutiérrez-Ortiz C, Méndez A, Rodrigo-Ray S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020. https://doi.org/10.1212/WNL0000000000009619.CrossRefPubMed

37.

Balestrino R, Rizzone H, Zibetti M, et al. Onset of COVID-19 with impaired consciousness and ataxia: a case report. J Neurol. 2020. https://doi.org/10.1007/s00415-020-09879-0.CrossRefPubMedPubMedCentral

38.

Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine. 2020. https://doi.org/10.1016/j.eclinm.2020.100527.CrossRefPubMedPubMedCentral

39.

Pouletty M, Borocco C, Ouldali A, et al. Pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicenter cohort. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217960.CrossRefPubMed

40.

Toublana J, Poirault C, Corsta A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;2020:m2094.CrossRef

41.

Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc. 2020. https://doi.org/10.1093/jpids/piaa069.CrossRefPubMed

42.

Chen TH. Neurological involvement associated with COVID-19 infection in children. J Neurol Sci. 2020. https://doi.org/10.1016/j.jns.2020.117096.CrossRefPubMedPubMedCentral

43.

Ahmad I, Rathore FA. Neurological manifestations and complications of COVID 19: a literature review. J Clin Neurosci. 2020;77:13–6. https://doi.org/10.1016/j.jocn.2020.05.017.CrossRef

44.

Montalvan V, Lee J, Bueso T, et al. Neurological manifestations of COVID 19 and other coronavirus infections. Clin Neurol Neurosurg. 2020. https://doi.org/10.1016/j.clineuro.2020.105921.CrossRefPubMedPubMedCentral

45.

Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767–703. https://doi.org/10.1016/S1474-4422920)30221-0.CrossRefPubMedPubMedCentral

46.

Roman GC, Spencer PS, Reis J, et al. The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci. 2020. https://doi.org/10.1016/j,jns.2020.116004.CrossRefPubMedPubMedCentral

47.

Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020. https://doi.org/10.1016/j.jns.2020.116032.CrossRefPubMedPubMedCentral

48.

Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19. Pandemic and the use of MS disease-modifying therapies. MSARD. 2020. https://doi.org/10.1016/j.msard.2020.102073.CrossRefPubMed

49.

Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE. Lymphopenia and risk of infection and infection-related death in 98 344 individuals from prospective Danish population-based study. PLoS Med. 2018;15(11):e1002685.CrossRefPubMedPubMedCentral

50.

Samaha R, Kattan J. Hematopoietic stem cell transplantation dilemma during the COVID-19 era. Future Oncol. 2020. https://doi.org/10.2217/fon-2020-0414.CrossRefPubMed

51.

Contentti EC, Correa J. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: a new challenge. MSARD. 2020. https://doi.org/10.1016/j.msard.2020.102097.CrossRef

52.

Dubbioso R, Nobile-Orazio E, Manganelli F, et al. Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral System Association (ASNP). Neurol Sci. 2020;41:1345–8.CrossRefPubMed

53.

International MG/COVID-19 Working Group. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020. https://doi.org/10.1016/j.jns2020.1.116803

54.

Kuroda N. Epilepsy and COVID-19 associations and important considerations. Epilepsy Behav. 2020. https://doi.org/10.1016/j.yebeh.2020.107122.CrossRefPubMedPubMedCentral

55.

Qureshi AI, Abd-Allah F, Al-Senani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: insights from an international panel. Am J Emerg Med. 2020. https://doi.org/10.1016/j.ajem.2020.05.018.CrossRefPubMedPubMedCentral

56.

Papa SM, Brundin P, Fung VS, et al. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders. Mov Disord. 2020;35:711–5.CrossRefPubMedPubMedCentral

57.

Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s Disease: hidden sorrows and emerging opportunities. J Parkinson’s Dis. 2020;10:351–4.CrossRef

Title: SARS-CoV-2 Infection: Symptoms of the Nervous System and Implications for Therapy in Neurological Disorders
Author: Jacek Losy
Publication date: 01-06-2021
Publisher: Springer Healthcare
Keywords: Stroke
SARS-CoV-2
COVID-19
Headache
Encephalitis
Published in: Neurology and Therapy / Issue 1/2021
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-020-00225-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

SARS-CoV-2 Infection: Symptoms of the Nervous System and Implications for Therapy in Neurological Disorders

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Design of a Non-Interventional Study to Validate a Set of Patient- and Caregiver-Oriented Measurements to Assess Health Outcomes in Spinal Muscular Atrophy (SMA-TOOL Study)

Targeting of the Subthalamic Nucleus in Patients with Parkinson’s Disease Undergoing Deep Brain Stimulation Surgery

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study

Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study

Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report